– USA, CA – Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, announced the appointment of Isaac Ro to its Board of Directors.
About Isaac Ro
Isaac Ro is a Partner at Catalio Capital Management, where he has led multiple venture and private credit investments in breakthrough life science companies. He currently serves on the boards of PinkDx and PrognomiQ. Previously, he was Executive Chairman of Haystack Oncology, where he led the company through its successful acquisition by Quest Diagnostics in 2023.
Before Catalio, Isaac Ro served as CFO of Sema4 (NASDAQ: WGS), where he guided the company through its public listing in 2021 and the acquisition of GeneDx. He also held the role of CFO of Thrive Earlier Detection, where he led the company’s launch and subsequent sale to Exact Sciences in 2020.
Before Thrive, Mr. Ro led the U.S. Medical Technology and Life Science Tools equity research teams at Goldman Sachs from 2010 to 2019, and held a similar role at Leerink Partners before that.
Isaac Ro earned his B.A. in History and was a Pre-Med at Middlebury College.
About Seer
Seer, Inc. sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures.
For more: https://seer.bio/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.